<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

| Antibodies | Yes (indicate where provided: section/paragraph) | n/a |
|--|--|-----|
| For commercial reagents, provide supplier name, catalogue number and RRID, if available. | ALPL Antibody (AP1474C, Abgent); Rabbit anti VEGF Polyclonal antibody (19003-1-AP); | |
| | Rabbit anti p65 Polyclonal antibody(10745-1-AP); | |
| | FITC Goat Anti-Rabbit IgG(H+L)(Proteintech); | |
| | FITC Goat Anti-Mouse IgG(H+L)(Proteintech); | |
| Call materials | Voc /indicate where provided costion/paragraph) | n/a |

| Cell materials | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|-----|
| Cell lines: Provide species information, strain. | Number: MXC001 | |
| Provide accession number in repository OR | Cell line name: HEK293 human embryonic kidney cells | |
| supplier name, catalog number, clone number, | Species: Human | |
| OR RRID | Tissue source: Human embryonic kidney | |
| Primary cultures: Provide species, strain, sex of | Number: MXC001 | |
| origin, genetic modification status. | Cell line name: HEK293 human embryonic kidney cells | |
| | Species: Human | |
| | Tissue source: Human embryonic kidney | |
| | Morphological characteristics: epithelial cells | |
| | Microorganism and Mycoplasma Test: Negative | |

| Experimental animals | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID | | n/a |
| Animal observed in or captured from the field: Provide species, sex and age where possible | | n/a |
| Model organisms: Provide Accession number in repository (where relevant) OR RRID | | n/a |

| Plants and microbes | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens) | | n/a |
| Microbes: provide species and strain, unique accession number if available, and source | | n/a |

| Human research participants | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|-----|
| Identify authority granting ethics approval (IRB or | The study was proved by the ethics committee of the | |
| equivalent committee(s), provide reference number | Children's Hospital Affiliated to Chongqing Medical | |
| for approval. | University (ethical approval no: 2019; NLS research no: | |
| | 232). | |
| Provide statement confirming informed consent | Informed written consent was obtained from the | |
| obtained from study participants. | parents of each of the 5 children. | |
| Report on age and sex for all study participants. | Yes, three males and two females, with ages ranging | |
| | from 6 days to 2 years and 5 months | |
| | | |

Design

| Study protocol | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|-----|
| For clinical trials, provide the trial registration number OR cite DOI in manuscript. | | n/a |
| Laboratory protocol | Yes (indicate where provided: section/paragraph) | n/a |
| Provide DOI or other citation details if detailed step- by-step protocols are available. | | n/a |
| Experimental study design (statistics details) | Yes (indicate where provided: section/paragraph) | n/a |
| State whether and how the following have been done, or if they were not carried out. | | |
| Sample size determination | Yes | |
| Randomisation | | n/a |
| Blinding | | n/a |
| Inclusion/exclusion criteria | | n/a |
| Sample definition and in-laboratory replication | Yes (indicate where provided: section/paragraph) | n/a |
| State number of times the experiment was replicated in laboratory | three times | |
| Define whether data describe technical or biological replicates | biological replicates | |
| Ethics | Yes (indicate where provided: section/paragraph) | n/a |
| Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | | n/a |
| Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | | n/a |
| Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. | The peripheral blood samples were collected from the children and their parents and sent to a third-party testing company for whole-exome sequencing, and informed written consents were obtained from the parents of each of the 5 children. | |
| Dual Use Research of Concern (DURC) | Yes (indicate where provided: section/paragraph) | n/a |
| If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval | | n/a |

<u>Analysis</u>

| Attrition | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| State if sample or data point from the analysis is | | n/a |
| excluded, and whether the criteria for exclusion were | | |
| determined and specified in advance. | | |

| Statistics | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| Describe statistical tests used and justify choice of | | n/a |
| tests. | | |

| Data Availability | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| State whether newly created datasets are available, | | n/a |
| including protocols for access or restriction on | | |
| access. | | |
| If data are publicly available, provide accession | | n/a |
| number in repository or DOI or URL. | | |
| If publicly available data are reused, provide | | n/a |
| accession number in repository or DOI or URL, where | | |
| possible. | | |

| Code Availability | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| For all newly generated code and software essential | | |
| for replicating the main findings of the study: | | |
| State whether the code or software is available. | | n/a |
| If code is publicly available, provide accession | | n/a |
| number in repository, or DOI or URL. | | |

Reporting

| Adherence to community standards | Yes (indicate where provided: section/paragraph) | n/a |
|---|--|-----|
| MDAR framework recommends adoption of | | |
| discipline-specific guidelines, established and | | |
| endorsed through community initiatives. Journals | | |
| have their own policy about requiring specific | | |
| guidelines and recommendations to complement | | |
| MDAR. | | |
| State if relevant guidelines (eg., ICMJE, MIBBI, | ICMJE guidelines were followed, as the journal follows | |
| ARRIVE) have been followed, and whether a checklist | ICMJE recommendations for publication | |
| (eg., CONSORT, PRISMA, ARRIVE) is provided with | | |
| the manuscript. | | |

| Article information: http://dx.doi.org/10.21037/atm-21-2096 | |
|--|--|
| | |
| | |
| | |